BCG: The Vaccine with a Century-Long History | Community Health

The BCG vaccine, developed by Albert Calmette and Camille Guérin in the early 20th century, has been a cornerstone in the fight against tuberculosis (TB) for over a century. With a Vibe score of 80, indicating significant cultural energy, the vaccine has undergone numerous transformations, from its initial use in France in 1921 to its current application in over 100 countries. Despite its widespread use, the BCG vaccine remains a topic of debate, with some questioning its efficacy in adults and others highlighting its potential as a treatment for other diseases, such as type 1 diabetes and multiple sclerosis. As of 2022, the World Health Organization (WHO) reports that BCG vaccination has been administered to over 100 million children worldwide, with a significant reduction in TB-related deaths. However, the vaccine's controversy spectrum is high, with ongoing discussions about its effectiveness and potential side effects. The influence flow of the BCG vaccine can be seen in the work of scientists such as Robert Koch, who first identified the bacteria causing TB, and the ongoing research into new TB treatments, such as the M72/AS01E vaccine, which has shown promising results in clinical trials.